Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Completed Research: PRACTICE MANAGEMENT RESEARCH
Abstract #CR05

Impact of a Remote Oncology Clinical Pharmacist Program in 4 Community Oncology Practices

JHOP - March 2022 Vol 12 Special Feature - HOPA Abstracts

Presenter: Melissa Carroll, PharmD, BCPS, Senior Clinical Pharmacist, McKesson/US Oncology Network

Co-Authors: Shannon Hough, PharmD, BCOP, Director, ClinReview and Clinical Content, McKesson/US Oncology Network; Joshua Howell, PharmD, BCOP, Vice President, Pharmacy and Clinical Programs, McKesson/US Oncology Network; Elizabeth Koselke, PharmD, BCOP, Senior Clinical Pharmacist, McKesson/US Oncology Network; Julianna Kula, PharmD, BCOP, Senior Clinical Pharmacist, McKesson/US Oncology Network

BACKGROUND: The impact and role of a clinical pharmacist in a community oncology setting is not well-described in the literature. The US Oncology Network recently implemented a centralized clinical pharmacist review program (ClinReview) to provide oncology clinical pharmacist services to community oncology practices.

OBJECTIVE: To evaluate the impact of remote clinical reviews by oncology pharmacists in community oncology practices.

METHOD: Oncology-trained clinical pharmacists reviewed electronic files for recently placed or modified chemotherapy regimen orders within 4 community oncology practices. The ClinReview pharmacists identified opportunities to modify ordered therapy, based on clinical variables, waste reduction, or financial stewardship. The recommendations were discussed with the treating oncologist at the community oncology practice or modified the regimen, if permitted by approved practice policy. Each pharmacist was appointed at half full-time equivalents. Financial and workload metrics were tracked to monitor the impact of the pharmacist interventions.

RESULTS: In 28 weeks, 2234 reviews were documented, and 1038 (46.5%) required modification by a pharmacist. The recommended modifications included 440 (42%) clinical change, 433 (42%) dose rounding, and 165 (16%) medication substitution. The most common clinical changes included 146 (33%) recommendations for additional monitoring, 137 (31%) modifications to supportive care, and 106 (24%) modifications to anticancer medication dose or frequency. Of these clinical recommendations, 235 (53%) were identified by the ClinReview pharmacist as directly influencing patient safety. The clinical pharmacist was remotely integrated into the care team, influencing complex patient care decisions, such as anticancer regimen selection and dosing. The financial impact of the pharmacist resulted in margin improvements totaling $522,473, and a reduction of $2,766,001 in the total cost of care in medication expenses. The expense of the pharmacists during this period was $117,571. To date, the return on investment for the pharmacists compared with the margin improvement was 444%.

CONCLUSION: Community oncology practices seek to provide high-value care in a resource-constrained model. An oncology clinical pharmacist is a cost-effective and clinically invaluable member of the care team in community oncology practices. Pharmacists identified opportunities to improve medication safety, drug regimen optimization, and demonstrated substantial financial impact on small-scale budgets in community oncology practices. Oncology-trained pharmacists are chemotherapy experts who are well-equipped to review clinical orders in a complex patient population at risk for medication-related adverse effects.

Related Items
HOP(A) Springs Eternal
Bryna Delman Ewachiw, PharmD, BCOP, Mark L. Zangardi, PharmD, BCOP
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in Editorial, HOPA Abstracts
A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Lymphoma
Evaluation of Empiric Double Coverage with Tobramycin for Adult Patients with Febrile Neutropenia
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Treatment Patterns, Real-World Outcomes, and Resource Use in Patients with Non–MSI-High or Mismatch Repair Proficient Advanced Endometrial Cancer
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Gynecologic Cancers
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Impact of PGY2 Oncology Pharmacy Residents’ Learning Experiences During the COVID-19 Pandemic
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Integrated Health-System Specialty Pharmacy Support in Reducing Financial Toxicity of Oral Oncolytic Therapy
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Perceptions of PGY2 Oncology Programs on Financial Toxicity Education and Preparedness
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Pharmacist-Led Oral Chemotherapy Monitoring Pilot Study and Assessment of Patient-Reported Outcomes and Adherence
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Chemotherapy
The Impact of a Comprehensive Immunotherapy Continuing Education Curriculum on Pharmacists’ Knowledge, Competence, and Confidence
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Immunotherapy
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.